Emergent Technologies Inc. and Pinpoint Med Inc. Announce Collaboration on Interventional Catheter Device

Emergent Technologies Inc. (ETI) of Austin, in partnership with Pinpoint Med Inc. (PMI) of Glil Yam, Israel, is set to develop an innovative interventional catheter device utilizing Selenium's patented technology. This groundbreaking device is designed to address the pressing need for a cost-effective and safe solution to debulking chronic total occlusions of blood vessels, a condition that often requires bypass surgery. The development of this device marks a significant convergence of two technologies, with Selenium's patented coating technology being applied to PMI's catheter devices.

Key Takeaways:

• ETI has agreed with PMI to develop an interventional catheter device employing Selenium's patented technology.
• The device aims to provide a cost-effective and safe solution to debulking chronic total occlusions of blood vessels, a condition that currently requires bypass surgery in most patients.
• Selenium's patented coating technology will be applied to PMI's catheter devices, utilizing catalytic production of locally toxic super-oxide radicals to inhibit bacteria, viruses, cellular, and biofilm growth and formation.
• ETI formed Selenium Ltd. through its third investment fund, WesTech Ventures I, and manages it from its Austin, Texas, headquarters.
• Pinpoint Med Inc. was formed by Seed Venture Partners, a venture capital firm specializing in forming, funding, and commercializing European institutional and university-originated medical device companies.
• Medgenesis Partners Ltd. is the medical device business accelerator managing both ETI and PMI, with its headquarters in Tel-Aviv, Israel and Brussels, Belgium.

Statistics:

• 1 in 3 patients with chronic total occlusions of blood vessels require bypass surgery.
• Selenium's patented coating technology is being applied to PMI's catheter devices to enhance reliability, non-toxicity, non-leaching, and suitability for controlled local delivery.
• The collaboration will utilize catalytic production of locally toxic super-oxide radicals to inhibit bacteria, viruses, cellular, and biofilm growth and formation.
• 1 application of Selenium's technology addresses an industry need for device coatings which are more reliable, non-toxic, non-leaching, and suitable for controlled local delivery.

Sources:

• Emergent Technologies Inc. (ETI) of Austin
• Pinpoint Med Inc. (PMI) of Glil Yam, Israel
• Medgenesis Partners Ltd. of Tel-Aviv, Israel and Brussels, Belgium
• Seed Venture Partners of Luxembourg
• WesTech Ventures I of Austin, Texas